title: 18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes.
abstract: OBJECTIVE
  To determine whether a correlation exists between maximum standardized uptake value (SUVmax) on (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) and the subtypes of breast cancer.
  
  
  METHODS
  This retrospective study involved 548 patients (mean age 51.6 years, range 21-81 years) with 552 index breast cancers (mean size 2.57 cm, range 1.0-14.5 cm). The correlation between (18)F-FDG uptake in PET/CT, expressed as SUVmax, and immunohistochemically defined subtypes (luminal A, luminal B, human epidermal growth factor receptor 2 (HER2) positive and triple negative) was analyzed.
  
  
  RESULTS
  The mean SUVmax value of the 552 tumours was 6.07 ± 4.63 (range 0.9-32.8). The subtypes of the 552 tumours were 334 (60%) luminal A, 66 (12%) luminal B, 60 (11%) HER2 positive and 92 (17%) triple negative, for which the mean SUVmax values were 4.69 ± 3.45, 6.51 ± 4.18, 7.44 ± 4.73 and 9.83 ± 6.03, respectively. In a multivariate regression analysis, triple-negative and HER2-positive tumours had 1.67-fold (P < 0.001) and 1.27-fold (P = 0.009) higher SUVmax values, respectively, than luminal A tumours after adjustment for invasive tumour size, lymph node involvement status and histologic grade.
  
  
  CONCLUSIONS
  FDG uptake was independently associated with subtypes of invasive breast cancer. Triple-negative and HER2-positive breast cancers showed higher SUVmax values than luminal A tumours.
  
  
  CONCLUSIONS
  • (18) F-FDG PET demonstrates increased tissue glucose metabolism, a hallmark of cancers. • Immunohistochemically defined subtypes appear significantly associated with FDG uptake (expressed as SUV max ). • Triple-negative tumours had 1.67-fold higher SUV max values than luminal A tumours. • HER2-positive tumours had 1.27-fold higher SUV max values than luminal A tumours.
authors.affiliation: Department of Radiology, Seoul National University College of Medicine, 28 Yongon-dong, Chongno-gu, Seoul, 110-744, Korea.
authors.forename: Hye Ryoung
authors.initials: HR
authors.lastname: Koo
authors.forename: Jeong Seon
authors.initials: JS
authors.lastname: Park
authors.forename: Keon Wook
authors.initials: KW
authors.lastname: Kang
authors.forename: Nariya
authors.initials: N
authors.lastname: Cho
authors.forename: Jung Min
authors.initials: JM
authors.lastname: Chang
authors.forename: Min Sun
authors.initials: MS
authors.lastname: Bae
authors.forename: Won Hwa
authors.initials: WH
authors.lastname: Kim
authors.forename: Su Hyun
authors.initials: SH
authors.lastname: Lee
authors.forename: Mi Young
authors.initials: MY
authors.lastname: Kim
authors.forename: Jin You
authors.initials: JY
authors.lastname: Kim
authors.forename: Mirinae
authors.initials: M
authors.lastname: Seo
authors.forename: Woo Kyung
authors.initials: WK
authors.lastname: Moon
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001706:Biopsy; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism* / Q000473:pathology; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals / Q000378:metabolism*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed / Q000379:methods; D064726:Triple Negative Breast Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism / Q000473:pathology; D055815:Young Adult
chemical_list: D019788:Fluorodeoxyglucose F18; D019275:Radiopharmaceuticals; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human